Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 14/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | RAPGEF3 | O95398 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.80 |
| ▸ | PDE4A | P27815 | 1/20 | 0.78 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.78 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.78 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclic Adenosine Monophosphate SCHEMBL18716064 | 1.00 | STING1 (1.00) | STING1LMNARAPGEF3KMT2AGMNN | |
| SCHEMBL15893189 | 1.00 | STING1 (1.00) | STING1LMNARAPGEF3KMT2AGMNN | |
| SCHEMBL18934079 | 1.00 | STING1 (1.00) | STING1LMNARAPGEF3KMT2AGMNN | |
| SCHEMBL22434642 | 1.00 | STING1 (1.00) | STING1LMNARAPGEF3KMT2AGMNN | |
| Cyclic Adenosine Monophosphate SCHEMBL23829653 | 1.00 | STING1 (1.00) | STING1LMNARAPGEF3KMT2AGMNN | |
| Cyclic Adenosine Monophosphate SCHEMBL23829820 | 1.00 | STING1 (1.00) | STING1LMNARAPGEF3KMT2AGMNN | |
| Cyclic Adenosine Monophosphate SCHEMBL23829591 | 1.00 | STING1 (1.00) | STING1LMNARAPGEF3KMT2AGMNN | |
| Cyclic Adenosine Monophosphate SCHEMBL23829670 | 1.00 | STING1 (1.00) | STING1LMNARAPGEF3KMT2AGMNN | |
| Cyclic Adenosine Monophosphate SCHEMBL23829673 | 1.00 | STING1 (1.00) | STING1LMNARAPGEF3KMT2AGMNN | |
| Cyclic Adenosine Monophosphate SCHEMBL20912149 | 1.00 | STING1 (1.00) | STING1LMNARAPGEF3KMT2AGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11819550-B2 | Liquid protein formulations containing cyclic adenosine monophosphate (cAMP) or adenosine triphosphate (ATP) | EAGLE BIOLOGICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20180153997-A1 | Liquid Protein Formulations Containing Organophosphates | EAGLE BIOLOGICS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9913905-B2 | Liquid pharmaceutical formulations for injection comprising thiamine pyrophosphate 1-(3-aminopropyl)-2-methyl-1H-imidazole and uses thereof | EAGLE BIOLOGICS, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-20170095580-A1 | TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-04-06 | — | — | US | disclosed |
| US-9261482-B1 | Gradient elution moving boundary electrophoresis for use with complex samples and detection of toxins | APPLIED RESEARCH ASSOCIATES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150071921-A1 | LIQUID PROTEIN FORMULATIONS CONTAINING ORGANOPHOSPHATES | EAGLE BIOLOGICS, INC. | 2015-03-12 | — | — | US | disclosed |
| US-20150071921-A1 | LIQUID PROTEIN FORMULATIONS CONTAINING ORGANOPHOSPHATES | EAGLE BIOLOGICS, INC. | 2015-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819550-B2 | Liquid protein formulations containing cyclic adenosine monophosphate (cAMP) or adenosine triphosphate (ATP) | PDE7A, PDE8A, PDE8B | STING1 234/4885LMNA 2108/4885RAPGEF3 174/4885 |
| US-20150071921-A1 | LIQUID PROTEIN FORMULATIONS CONTAINING ORGANOPHOSPHATES | IGFBP1, IGFBP5, IGF2BP1 | STING1 680/4885LMNA 2987/4885RAPGEF3 2000/4885 |
| US-20170095580-A1 | TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | FCGR2A, PAICS, CD47 | STING1 4200/4885LMNA 2921/4885RAPGEF3 3435/4885 |
| US-20180153997-A1 | Liquid Protein Formulations Containing Organophosphates | IGFBP1, IGFBP5, IGF2BP1 | STING1 680/4885LMNA 2987/4885RAPGEF3 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.